Supernus Pharmaceuticals, INC Form 4 insider transactions

Supernus Pharmaceuticals' Sr. VP of IP, CSO, Padmanabh P. Bhatt, reported the acquisition of 1,500 shares and the disposition of 710 shares for tax purposes on December 18, 2025.

Supernus Pharmaceuticals Director Charles W. Newhall III exercised options to acquire 15,000 shares of common stock at $12.98 per share.

Supernus Pharmaceuticals' Senior VP of IP and CSO, Padmanabh P. Bhatt, reported the acquisition of 1,500 performance share units and beneficial ownership of 13,718 common shares.

Supernus Pharmaceuticals CEO Jack Khattar exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

Supernus Pharmaceuticals Director Charles W. Newhall III sold 25,000 shares of common stock on October 9, 2025, under a pre-arranged 10b5-1 trading plan.

Supernus Pharmaceuticals CEO Jack Khattar reported the settlement of performance share units and related tax withholdings, increasing his direct beneficial ownership.

Supernus Pharmaceuticals CEO Jack Khattar exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

Supernus Pharmaceuticals CEO Jack Khattar exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Supernus Pharmaceuticals CEO Jack A. Khattar exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

Supernus Pharmaceuticals CEO Jack Khattar exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Supernus Pharmaceuticals' CMO Jonathan Rubin reported the settlement of performance share units and a related stock disposition for tax purposes.

Supernus Pharmaceuticals President and CEO Jack A. Khattar exercised employee stock options and subsequently sold a portion of the acquired common stock under a pre-established 10b5-1 trading plan.

Supernus Pharmaceuticals' President and CEO, Jack A. Khattar, exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

A Supernus Pharmaceuticals executive exercised stock options and subsequently sold 5,000 shares of common stock for a profit.

Supernus Pharmaceuticals' Chief Medical Officer, Jonathan Rubin, reported changes in his beneficial ownership, including the acquisition of Performance Share Units and shares through an employee plan.

Supernus Pharmaceuticals CEO Jack Khattar reported the vesting of 39,320 Performance Share Units, increasing his beneficial ownership.

Supernus Pharmaceuticals' President and CEO, Jack A. Khattar, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 plan.

Supernus Pharmaceuticals CEO Jack Khattar exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 plan.

Supernus Pharmaceuticals CEO Jack Khattar sold shares after exercising stock options under a pre-arranged 10b5-1 plan.

Supernus Pharmaceuticals Director Charles W. Newhall III executed a pre-planned sale of 3,588 shares of common stock for approximately $161,497.

Supernus Pharmaceuticals' Sr. VP of IP and CSO, Padmanabh P. Bhatt, acquired 1,250 common shares through performance unit settlement, with 581 shares withheld for taxes.

A Supernus Pharmaceuticals executive exercised stock options and subsequently sold the acquired shares, as disclosed in a recent SEC Form 4 filing.

Supernus Pharmaceuticals Director Charles W. Newhall III sold 1,000 shares of common stock for a weighted average price of $45.00 under a pre-arranged 10b5-1 trading plan.

Supernus Pharmaceuticals CEO Jack Khattar sold 1,000 shares of common stock for $45.00 per share after exercising options, as part of a pre-scheduled 10b5-1 trading plan.

Supernus Pharmaceuticals Director Charles W. Newhall III sold 1,412 shares of common stock for approximately $45.00 per share, executed under a pre-arranged 10b5-1 trading plan.

Supernus Pharmaceuticals' Senior Vice-President and CFO, Timothy C. Dec, sold 11,780 shares of common stock for approximately $44.49 per share through a pre-arranged trading plan.

Supernus Pharmaceuticals CEO Jack A. Khattar exercised stock options and sold a portion of his shares under a pre-arranged 10b5-1 trading plan.

Supernus Pharmaceuticals Director Bethany Sensenig sold 5,369 shares of common stock for $42.25 per share under a pre-arranged 10b5-1 trading plan.

Supernus Pharmaceuticals Director Frederick M. Hudson sold 7,457 shares of common stock for a weighted average price of $42.26 per share.

Supernus Pharmaceuticals' Sr. VP of IP and CSO, Padmanabh P. Bhatt, acquired 1,250 Performance Share Units and increased common stock holdings to 13,049 shares.